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We read with interest the letter by Agarwal and Nath [1] in
response to our commentary [2] analyzing current evidence
for drotrecogin alfa (activated) (DrotAA) in the treatment of
severe sepsis. Agarwal and Nath argue that our meta-analysis
should have used a fixed-effects model, which ignores
between-study heterogeneity, rather than a more conservative
random-effects model, which includes it. Such a model
shows significant benefit for DrotAA in patients with severe
sepsis and at a high risk of death defined either by an Acute
Physiology and Chronic Health Evaluation (APACHE) II score
of 25 or more, or at least two organ dysfunctions.
Agarwal and Nath’s letter highlights the surprising degree of
statistical heterogeneity that remains between the Adminis-
tration of Drotrecogin Alfa (Activated) in Early Stage Severe
Sepsis (ADDRESS) trial [3] and the Recombinant Human
Activated Protein C Worldwide Evaluation of Severe Sepsis
(PROWESS) trial [4] results despite minimal methodologic
differences between these trials and further minimization of
clinical heterogeneity by selecting a more uniform subgroup
of patients with severe sepsis and a high risk of death. In
particular, for the subgroup with an APACHE II score of 25 or
more, I2 (the percentage of total variation in results across
studies that is due to heterogeneity rather than chance [5]) is
very high (84%). Given this degree of heterogeneity, we feel
that one should account for, rather than ignore, its effects
when pooling results.
The APACHE II subgroup effect in PROWESS was one of
about 80 prospectively defined subgroup comparisons [6].
Using other definitions of high risk, the difference in treatment
effect between high-risk and low-risk subgroups in PROWESS
was not statistically significant (for example, patients with
multiple organ failure) and in some cases not even directionally
consistent (for example, patients requiring mechanical
ventilation or vasopressor support) [7]. If the APACHE II high-
risk and low-risk subgroup effect in PROWESS is due to
chance, then the best estimate of the effect of DrotAA for any
patient is the overall pooled result incorporating all patients.
Interestingly, although the degree of between-study hetero-
geneity is significant when the overall data from all four trials
presented in Figure 1 [2] are pooled (I2 = 59%), it disappears
if PROWESS is excluded (I2 = 0%).
Is there a role for DrotAA in severe sepsis? The inconsistent
trial results and increased risk of serious bleeding highlight the
importance of identifying patients for whom the benefits of
DrotAA outweigh the risks. The high variability and very low
proportion of patients with severe sepsis receiving DrotAA in
many western European countries [8] suggest that many
clinicians are having difficulties identifying such patients. We
agree with Agarwal and Noth’s [1] second point, namely that a
meta-analysis using individual patient data and adjusting for
baseline covariates would be an important first step to identify
appropriate patients for DrotAA. However, such an analysis
would be primarily hypothesis generating, and additional trials
would still be required to provide definitive guidance on
appropriate patient selection. In any case, we believe that
evidence for the routine use of DrotAA should be based on
consistent clinical trials and should not depend on the use of a
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particular meta-analytic statistical model, particularly one that
does not account for between-trial heterogeneity.
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